Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157935 · ClinicalTrials.gov registry record · Phase 3
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,026
- Enrollment target
NCT02157935 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,026 participants.
The verdict
NCT02157935, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,026 participants
- Enrollment target
Study Summary
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
Interventions
- DRUG Symbicort
- DRUG Formoterol turbohaler
- OTHER Placebo for Symbicort pMDI
- OTHER Placebo for Formoterol Turbohaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,026 participants |
| Start Date | 2014-06-27 |
| Est. Completion | 2016-02-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02157935
The ClinicalTrials.gov registry entry for NCT02157935 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,026 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Symbicort is the first listed.
NCT02157935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02157935 about?
NCT02157935 is a clinical study titled "Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease". Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
What is the current status of trial NCT02157935?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,026 participants. The study started on 2014-06-27. Estimated completion is 2016-02-08.
What interventions are being tested in trial NCT02157935?
The interventions under investigation include: Symbicort (DRUG), Formoterol turbohaler (DRUG), Placebo for Symbicort pMDI (OTHER), Placebo for Formoterol Turbohaler (OTHER).
Who is sponsoring clinical trial NCT02157935?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.